Myelodysplastic syndrome classification: Difference between revisions
Jump to navigation
Jump to search
Line 59: | Line 59: | ||
* Refractory neutropenia (RN) | * Refractory neutropenia (RN) | ||
* Refractory thrombocytopenia (RT) | * Refractory thrombocytopenia (RT) | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with single lineage dysplasia (MDS-SLD) | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory anemia with ring sideroblasts (RARS) | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with ring sideroblasts (MDS-RS) | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with ring sideroblasts (MDS-RS) | ||
* MDS-RS-SLD | * MDS-RS-SLD | ||
* MDS-RS-MLD | * MDS-RS-MLD | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory cytopenias with multilineage dysplasia | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with multilineage dysplasia (MDS-MLD) | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|Refractory anemia with excess blasts (RAEB) | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|Refractory anemia with excess blasts (RAEB) | ||
Line 76: | Line 76: | ||
*MDS-EB-2 | *MDS-EB-2 | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|MDS with isolated del(5q) | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|MDS with isolated del(5q) | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|MDS, unclassifiable (MDS-U) | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|MDS, unclassifiable (MDS-U) | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|Refractory cytopenia of childhood (provisional) | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left"|Refractory cytopenia of childhood (provisional) | ||
|} | |} | ||
Revision as of 19:51, 14 December 2018
Myelodysplastic syndrome Microchapters |
Differentiating Myelodysplastic syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Myelodysplastic syndrome classification On the Web |
American Roentgen Ray Society Images of Myelodysplastic syndrome classification |
Risk calculators and risk factors for Myelodysplastic syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Myelodysplastic syndrome may be classified into several subtypes based on the French-American-British (FAB) classification and World Health Organization the (WHO) classification methods.
Classification
French-American-British (FAB) Classification
- Myelodysplastic syndrome may be classified according to the French-American-British classification into five groups: Refractory anemia, refractory anemia with ring sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.[1][2]
- The table below lists FAB classification for myelodysplastic syndrome:[1][2]
Name | Description |
---|---|
Refractory anemia |
|
Refractory anemia with ring sideroblasts (RARS) |
|
Refractory anemia with excess blasts (RAEB) |
|
Refractory anemia with excess blasts in transformation (RAEB-T) |
|
Chronic myelomonocytic leukemia (CMML) |
|
WHO Classification
- Myelodysplastic syndromes may be classified according to the WHO classification method into eight subtypes: Refractory anemia, refractory cytopenia with unilineage dysplasia, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, refractory cytopenia of childhood, and unclassifiable myelodysplastic syndrome.[2]
- The table below lists World Health Organiztion classification for myelodysplastic syndrome:[2][3]
2008 | 2016 |
---|---|
Refractory cytopenia with unilineage dysplasia (RCUD)
|
MDS with single lineage dysplasia (MDS-SLD) |
Refractory anemia with ring sideroblasts (RARS) | MDS with ring sideroblasts (MDS-RS)
|
Refractory cytopenias with multilineage dysplasia | MDS with multilineage dysplasia (MDS-MLD) |
Refractory anemia with excess blasts (RAEB)
|
MDS with excess blasts (MDS-EB)
|
MDS with isolated del(5q) | MDS with isolated del(5q) |
MDS, unclassifiable (MDS-U) | MDS, unclassifiable (MDS-U) |
Refractory cytopenia of childhood (provisional) | Refractory cytopenia of childhood (provisional) |
References
- ↑ 1.0 1.1 Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015
- ↑ 2.0 2.1 2.2 2.3 Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015
- ↑ Hong M, He G (September 2017). "The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes". J Transl Int Med. 5 (3): 139–143. doi:10.1515/jtim-2017-0002. PMC 5655460. PMID 29085786.